tiprankstipranks
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
PremiumPress ReleasesCellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
2M ago
Cellectar Biosciences reports Q1 EPS (74c), consensus ($1.00)
PremiumThe Fly
Cellectar Biosciences reports Q1 EPS (74c), consensus ($1.00)
2M ago
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
PremiumPress Releases
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
2M ago
Options Volatility and Implied Earnings Moves Today, March 27, 2024
PremiumMarket NewsOptions Volatility and Implied Earnings Moves Today, March 27, 2024
3M ago
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
PremiumPress Releases
Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update
3M ago
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
PremiumMarket News
Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
4M ago
Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
PremiumPress ReleasesCellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer
4M ago
Cellectar Biosciences reports results from Phase 1 study of iopofosine I 131
PremiumThe Fly
Cellectar Biosciences reports results from Phase 1 study of iopofosine I 131
4M ago
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
PremiumPress Releases
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100